Autor según el artículo: Gonzalez-Montes, Y; Osca-Gelis, G; Rodriguez-Romanos, R; Villavicencio, A; González-Bártulos, M; Llopis, F; Clapes, V; Oriol, A; Sureda, A; Escoda, L; Sarrà, J; Garzó, A; Lloveras, N; Gómez, B; Granada, I; Gallardo, D
Departamento: Medicina i Cirurgia
Autor/es de la URV: Sarra Escarre, Jose
Palabras clave: Bone marrow microenvironment Cd200 polymorphisms Disease Expression Genes Glycoprotein Immune checkpoint Immune disfunction Immunity Multiple myeloma Risk Susceptibility Therapeutic target
Resumen: Immune dysfunction in patients with MM affects both the innate and adaptive immune system. Molecules involved in the immune response pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. However, few data are available concerning the role of immune checkpoint molecules in predicting the myeloma control and immunological scape as mechanism of disease progression. We retrospectively analyzed the clinical impact of the CD200 genotype (rs1131199 and rs2272022) in 291 patients with newly diagnosed MM. Patients with a CD200 rs1131199 GG genotype showed a median overall survival (OS) significantly lower than those with CC+CG genotype (67.8 months versus 94.4 months respectively; p: 0.022) maintaining significance in the multivariate analysis. This effect was specially detected in patients not receiving an autologous stem cell transplant (auto-SCT) (p < 0.001). In these patients the rs1131199 GG genotype negatively influenced in the mortality not related with the progression of MM (p: 0.02) mainly due to infections events.
Áreas temáticas: Biodiversidade Biotecnología Ciência de alimentos Ciências biológicas i Ciências biológicas ii Ciências biológicas iii Engenharias ii Engenharias iii Farmacia Immunology Immunology and allergy Interdisciplinar Medicina i Medicina ii Medicina iii Medicina veterinaria Nutrição Odontología Química Saúde coletiva Zootecnia / recursos pesqueiros
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: jose.sarra@urv.cat
Fecha de alta del registro: 2024-05-23
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1252445/full
Referencia al articulo segun fuente origial: Frontiers In Immunology. 15 1252445-
Referencia de l'ítem segons les normes APA: Gonzalez-Montes, Y; Osca-Gelis, G; Rodriguez-Romanos, R; Villavicencio, A; González-Bártulos, M; Llopis, F; Clapes, V; Oriol, A; Sureda, A; Escoda, L; (2024). CD200 genotype is associated with clinical outcome of patients with multiple myeloma. Frontiers In Immunology, 15(), 1252445-. DOI: 10.3389/fimmu.2024.1252445
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
DOI del artículo: 10.3389/fimmu.2024.1252445
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2024
Tipo de publicación: Journal Publications